Sotac Pharmaceuticals Ltd
Incorporated in 2015, Sotac Pharmaceuticals
Ltd manufactures and sells a wide range of pharmaceutical products[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 111
- High / Low ₹ 203 / 87.1
- Stock P/E 24.5
- Book Value ₹ 45.6
- Dividend Yield 0.00 %
- ROCE 19.3 %
- ROE 16.6 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 84.9 to 120 days.
- Working capital days have increased from 71.6 days to 161 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|
| 43.44 | 73.15 | 57.98 | 67.11 | 64.60 | |
| 40.58 | 65.13 | 49.73 | 57.15 | 55.97 | |
| Operating Profit | 2.86 | 8.02 | 8.25 | 9.96 | 8.63 |
| OPM % | 6.58% | 10.96% | 14.23% | 14.84% | 13.36% |
| 0.35 | -1.63 | 0.24 | 1.32 | 1.72 | |
| Interest | 0.61 | 0.58 | 0.90 | 1.01 | 0.98 |
| Depreciation | 1.11 | 1.13 | 1.63 | 2.51 | 2.61 |
| Profit before tax | 1.49 | 4.68 | 5.96 | 7.76 | 6.76 |
| Tax % | 0.00% | 29.91% | 24.66% | 25.90% | |
| 1.48 | 3.30 | 4.50 | 5.75 | 4.99 | |
| EPS in Rs | 6.43 | 14.35 | 5.59 | 5.20 | 4.52 |
| Dividend Payout % | 0.00% | 13.94% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 16% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 57% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 27% |
| Last Year: | 17% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 2.30 | 2.30 | 8.05 | 11.05 | 11.05 |
| Reserves | 2.51 | 4.80 | 12.94 | 37.22 | 39.33 |
| 6.68 | 7.39 | 10.66 | 11.17 | 10.49 | |
| 11.01 | 21.82 | 23.13 | 16.65 | 22.92 | |
| Total Liabilities | 22.50 | 36.31 | 54.78 | 76.09 | 83.79 |
| 6.42 | 8.80 | 14.09 | 17.67 | 16.98 | |
| CWIP | 0.00 | 0.00 | 0.04 | 0.05 | 0.05 |
| Investments | 0.00 | 0.00 | 4.00 | 11.50 | 15.53 |
| 16.08 | 27.51 | 36.65 | 46.87 | 51.23 | |
| Total Assets | 22.50 | 36.31 | 54.78 | 76.09 | 83.79 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| 2.22 | 3.58 | 8.54 | -19.79 | |
| -1.07 | -3.28 | -10.93 | -12.53 | |
| -1.17 | -0.30 | 11.97 | 23.36 | |
| Net Cash Flow | -0.02 | 0.00 | 9.57 | -8.96 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|
| Debtor Days | 52.68 | 62.57 | 72.40 | 119.71 |
| Inventory Days | 40.71 | 35.14 | 87.26 | 88.97 |
| Days Payable | 112.49 | 128.97 | 165.78 | 119.08 |
| Cash Conversion Cycle | -19.10 | -31.25 | -6.12 | 89.59 |
| Working Capital Days | 26.97 | 29.09 | 24.93 | 160.94 |
| ROCE % | 54.66% | 29.74% | 19.26% |
Documents
Announcements
-
Clarification - Financial Results
4 December 2024 - Exchange has sought clarification from Sotac Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. On …
-
Financial Result Updates
29 October 2024 - Sotac Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.
-
Outcome of Board Meeting
29 October 2024 - Sotac Pharmaceuticals Limited has informed regarding Board meeting held on October 29, 2024.
-
Board Meeting Intimation
24 October 2024 - SOTAC PHARMACEUTICALS LIMITED has informed about Board Meeting to be held on 29-Oct-2024 to consider and approve the Half Yearly Unaudited Financial results of the …
-
Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter
15 October 2024 - Sotac Pharmaceuticals Limited has informed regarding Submission of the Compliance Report on Corporate Governance
Business Overview:[1]
SPL specializes in manufacturing a broad range of pharmaceutical products across various therapeutic areas, including anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological treatments, antacids, anti-ulcer (PPI), anti-emetics, cardiac, antihypertensives, analgesic, antipyretic, anti-inflammatory, antibacterial, antiviral, general antibiotics (β-lactams and non-β-lactams), antifungal, and cephalosporins.